Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have earned a consensus recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $41.25.

ACRS has been the subject of several research analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a report on Thursday, May 25th. ValuEngine lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a report on Friday, June 16th. They issued an “overweight” rating and a $50.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/16/aclaris-therapeutics-inc-acrs-given-consensus-rating-of-hold-by-brokerages.html.

In related news, Director Andrew N. Schiff bought 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average cost of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 16.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ACRS. Teachers Advisors LLC boosted its stake in Aclaris Therapeutics by 24.9% in the 4th quarter. Teachers Advisors LLC now owns 17,249 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 3,435 shares during the period. Nationwide Fund Advisors boosted its stake in Aclaris Therapeutics by 8.3% in the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 510 shares during the period. Strs Ohio acquired a new position in Aclaris Therapeutics in the 1st quarter worth $629,000. Wells Fargo & Company MN boosted its stake in Aclaris Therapeutics by 91.3% in the 1st quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 5,900 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Aclaris Therapeutics by 269.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 3,500 shares during the period. 95.79% of the stock is owned by hedge funds and other institutional investors.

Shares of Aclaris Therapeutics (ACRS) traded down 2.31% during mid-day trading on Friday, hitting $25.83. The company had a trading volume of 913,104 shares. Aclaris Therapeutics has a one year low of $20.15 and a one year high of $33.25. The firm’s 50-day moving average price is $26.18 and its 200 day moving average price is $27.71. The company’s market capitalization is $690.59 million.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12. Analysts predict that Aclaris Therapeutics will post ($3.10) earnings per share for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.